Protocols for Assessing Radiofrequency Interactions with Gold Nanoparticles and Biological Systems for Non-invasive Hyperthermia Cancer Therapy

Stuart J. Corr1,2, Brandon T. Cisneros1,2, Leila Green1, Mustafa Raoof1, Steven A. Curley1,3
1Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center
2Department of Chemistry, Rice University
3Mechanical Engineering and Materials Science, Rice University

Correspondence to: Steven A. Curley at scurley@mdanderson.org

URL: http://www.jove.com/video/50480
DOI: doi:10.3791/50480

Keywords: Medicine, Issue 78, Electronics and Electrical Engineering, Life Sciences (General), Radiofrequency, Cancer, Nanoparticles, Hyperthermia, Gold

Date Published: 8/28/2013


Abstract

Cancer therapies which are less toxic and invasive than their existing counterparts are highly desirable. The use of RF electric-fields that penetrate deep into the body, causing minimal toxicity, are currently being studied as a viable means of non-invasive cancer therapy. It is envisioned that the interactions of RF energy with internalized nanoparticles (NPs) can liberate heat which can then cause overheating (hyperthermia) of the cell, ultimately ending in cell necrosis.

In the case of non-biological systems, we present detailed protocols relating to quantifying the heat liberated by highly-concentrated NP colloids. For biological systems, in the case of in vitro experiments, we describe the techniques and conditions which must be adhered to in order to effectively expose cancer cells to RF energy without bulk media heating artifacts significantly obscuring the data. Finally, we give a detailed methodology for in vivo mouse models with ectopic hepatic cancer tumors.

Introduction

The absorption of RF energy by biological tissue (due to their inherent electrical permittivity) results in elevated tissue temperatures as a function of time, which eventually leads to cell death by hyperthermia. It is hypothesized that cancer hyperthermia can be optimized through the use of targeted nanomaterials that internalize within the cancer cell and act as RF-thermal transducers, leaving the neighboring healthy, normal cells intact. Several reports have already shown that a variety of NPs can act as effective RF heat sources which aid in cancer necrosis.

In these regards, gold NPs (AuNPs)3-5, carbon nanotubes1, and quantum dots6, 7 have exhibited exciting characteristics when used in both in vitro and in vivo RF experiments. Although the exact nature of the heating mechanism of these NPs when exposed to an RF-field is still being debated, a series of fundamental experiments using AuNPs has placed great significance on both NP size and aggregation states. It was shown that only AuNPs with diameters <10 nm will heat when exposed to an RF-field8. Also, this heating mechanism is significantly attenuated when the AuNPs are aggregated. This aggregation condition was also validated within in vitro models that placed importance upon optimizing AuNP colloidal stability within endolysosomal intracellular compartments for efficacious RF therapy9. However, the techniques and experimental principles used to collect and assess this data can be problematic, especially in the case of validating RF heat profiles from NP colloids.

Several reports have shown that Joule heating of the background ionic suspension that the NPs are suspended in can be the main source of RF heat production and not the NPs themselves9-12. Although our recent paper8 has validated the use of RF interactions in generating heat from AuNPs of diameters less than 10 nm, we aim to describe these protocols in more detail throughout this article.

We also demonstrate the protocols and techniques needed to evaluate the effectiveness of AuNPs as hyperthermic thermal agents in both in vitro and in vivo experiments for liver cancer models. Although we focus primarily on simple colloids of citrate-capped AuNPs, the same techniques can be applied to other AuNP hybrids such as antibody- and chemotherapy-conjugated complexes. By adhering to these principles the experimentalist should hopefully be able to rapidly evaluate the potential for any nanomaterial to be an effective RF-induced thermal hyperthermic agent.
Protocol

A complete experimental overview is depicted in Figure 1.

Further details are depicted in steps 1-3 below.

1. Assessing RF Heating of NP Colloids: AuNPs as an Example

1. In general, for each NP sample being investigated, first wash the sample several times through a centrifugation filter with deionized (DI) water to remove background ions and contaminants. All ions and contaminants will have been removed from the AuNP suspension when the liquid being washed out has similar RF heating rates (HRs) as DI water. This purification process also allows for higher concentrations of NPs to be obtained. It is worth noting that although using AuNPs in this example, the fundamental principles can be applied to other NP materials.

2. As an example, purify a 500 ml bottle of commercially available AuNPs of diameter 5 nm and then subject them to a 13.56 MHz RF field of electric-field strength 90 kV/m.
   1. Take ~125 ml from the stock AuNP solution and split between six 50 kDa centrifuge filter tubes. Centrifuge at 3,000 rpm. for 2 min 5 sec. Remove filtered buffer and refill filters with more stock solution. Repeat until all 500 ml has been filtered.
   2. Replace the filtered buffer with a similar volume of DI water and repeat approximately 8 times (or until the filtered buffer RF HRs are equivalent to DI water). Note, UV-Vis analysis can also be used to monitor contaminant adsorption peaks. Once the buffer contaminants have been fully removed, pipette approximately 0.5 ml DI water into each filter and resuspend the AuNPs by repeated pipetting. This should completely remove the AuNPs from the filter and allow for full resuspension. Combine all six suspensions into one 15 ml Eppendorf tube.
   3. Once the AuNPs have been purified and concentrated, analyze the sample using ICP-OES and/or ICP-MS, UV-vis and Zeta potential for data on concentration and NP stability, respectively. SEM and/or TEM analysis can also be used to obtain morphological data. Detailed sample preparation for these techniques can be found in the literature.*

3. Using the Kanzius RF system described in previous studies,** or derivations of this system, place a 1.3 ml cylindrical quartz cuvette so that the RF electric-field is in air (with no sample present) would be ~90 kV/m inside the cuvette. For a standard saline sample (0.9 % NaCl) the electric-field would be reduced to ~1.1 kV/m. These are the approximate conditions used to allow comparisons to be made between different systems.
   1. Pipette 1.3 ml of a 1,000 mg/l sample of purified AuNP colloid into the quartz cuvette and introduce this into the RF-field. This can be done by using a custom-built Teflon sample holder. Expose sample to the RF-field for a period of 120 sec or until the sample reaches 70 °C to prevent electrical arcing or rapid boiling. Capture the thermal imaging data (as well as control areas) using an IR camera & associated software. Repeat this procedure three times.
   2. Filter the sample through another 50 kDa centrifuge filter to extract the AuNPs from the DI water buffer. Re-expose the buffer to the RF-field, again three times. The difference in HRs between the AuNP colloid and the background DI water buffer determines the HR due to the AuNPs themselves. Expect to obtain HRs of ~0.3 °C/sec and 0.05 °C/sec to give an AuNP dependent HR of ~0.25 °C/sec. Resuspend the remaining AuNPs from the filter in 1.3 ml water for in vitro/vivo experiments.

2. Nanoparticle-assisted RF-induced Hyperthermia: In vitro Studies

1. These in vitro studies can be applied to any type of cancer cell type that form 2D monolayers. In this experiment use human hepatocellular carcinoma derived Hep3B cells.
   1. Plate ~50,000 cells in the front three wells of a 12-well plate with 1 ml of growth media. Repeat this 6 times (use three plates for NP studies and three plates as controls). Incubate at 37.5 °C for 24 hr before introducing the NPs. Sterilize NPs first using BioSafety Cabinet UV-light exposure for 5 min.
   2. Into each well introduce 0.1 ml of a 1,000 mg/L AuNP solution and leave for another 24 hr. Add 0.1 ml of water into each well of the control cell plates and also leave for 24 hr.
   3. After 24 hr have passed, aspirate the cell media and wash with PBS to remove any surface-bound AuNPs. Replace the cell media. Cells are now ready for RF exposure.

2. Place each 12-well cell pack within the RF-field. Wait until the cells have cooled to 31 °C. Turn on the RF generator and expose for 3.5 min. The final temperature of the cell media will be ~37 °C. Turn off the RF field. Remove the cells and place them in an incubator for 24 hr before analysis.
   1. Remove cells from the incubator and aspirate cell media. Add 1.6 ml of cell media to each well as well as 0.4 ml of MTT reagent. Incubate cells for 4 hr. Aspirate media and replace with 2 ml of Dimethyl sulfoxide (DMSO). Place the cell plates on a bench rocker and leave for 10 min to allow the DMSO to solubilize the MTT reagents. Finally, pipette 100 μl of each well into a 96-well plate and optically read the well at 570 nm using a plate reader such as the SPECTROstar Nano plate reader.

3. Nanoparticle-assisted RF-induced Hyperthermia: In vivo Studies

1. These in vivo studies can be applied to any type of cancer that forms solid tumors in an orthotopic or ectopic murine model. This experiment uses Hep3B liver cancer cells in an ectopic tumor BALB-C Nude mouse model.

2. Note: all in vivo experiments are executed in compliance with all relevant guidelines, regulations and regulatory agencies. Also, the protocol being demonstrated was performed under the guidance and approval of University of Texas M.D. Anderson Cancer Centers Institutional Animal Care and Use Committee (IACUC).
1. Grow an appropriate number of cells (~100 k) in a tissue culture flask with the appropriate growth medium. Incubate in a 37 °C incubator with 5 % CO₂ for the duration of cell culture.

2. Treat cells with trypsin (to detach from the flask) and produce a solution of 2 million cells for every 25 μl. Add an equal quantity of Matrigel (on ice) and mix thoroughly to prepare the final injection solution. Inject this solution into the desired position on the mouse's back and wait an appropriate amount of time for the tumors to grow to the desired size (2-4 weeks for most cells). Before RF exposure, BALB-C Nude mice should bear solid ectopic tumors 0.5-1 cm diameter.

3. Prepare the mice to be used (in this case BALB-C Nude mice) by anaesthetizing them with a solution of ketamine and xylazine by IP injection. While the mice are falling asleep, keep them in a temperature controlled chamber at 37 °C. 20 mice in total will be needed, all bearing similar size tumors. Ten mice will be used in conjunction with and without AuNPs (the latter being PBS injections only) while the remaining 10 mice will be split between RF-exposed and non RF-exposed controls: both groups with no AuNP injections.

   1. Once properly anaesthetized, inject the AuNPs directly into the tumor using a 1-cc syringe with a 27 G needle. The AuNP solution should be at a Au concentration of 200 mg/L in 0.1 ml of PBS. After injection, use a surgical swab to absorb blood and wipe the injection site with an alcohol wipe.

   2. Then mount the mouse to be treated on the receiving head of the RF generator. The mouse must be positioned so that the tumor is closest to the transmission head. Shield the areas that are not to be treated, as well as sensitive areas such as eyes, ears, and toes, with copper tape. Be sure that the copper tape is appropriately contacting the grounding plane so that no charge buildup occurs. Also, the exposure area must have a gap of at least 1 cm greater than the size of the desired treatment site.

   3. Position IR thermal camera so that the tumor and treatment area are visible. Turn on RF for 5 min. Record the resulting temperature curve. If therapy achieves temperatures greater than 42 °C stop treatment immediately.

4. After RF exposure recover the mice from anesthesia in a warm chamber until they are conscious.

   1. Repeat the experiment with the same mice 48 hr later (steps 3.3.1 - 3.4.1).

   2. After the experiment, euthanize the mice in accordance with institutional protocols and procedures. Record the weight of the tumor. For histological analysis fix the tumors using formalin and embed them in paraffin. Tumor sections are typically stained with hematoxylin and eosin and for targets relevant to gauging therapeutic efficacy, e.g. Ki-67, cleaved caspase-3, etc.

**Representative Results**

1. Assessing RF heating of NP colloids: AuNPs as an example.

   After following section 1.1 - 1.2.3 expect to have a highly concentrated, stable, and purified solution of 5 nm and 10 nm diameter AuNPs. From the 500 ml as-purchased stock solution, expect to obtain at least 4 ml of solution at a concentration of 1,000 mg/L. The difference in HRs between the AuNPs and the background DI water buffer solution at this concentration should be ~0.25 °C/sec and 0.1 °C/sec for 5 nm and 10 nm AuNPs, respectively, as is shown in Figure 2.

2. Nanoparticle-assisted RF-Induced Hyperthermia: *In vitro* studies

   The results should ideally show that cells exposed to an RF field which have internalized AuNPs are less viable than the non-AuNP RF exposed cells. An example of such expected results are highlighted in Figure 3.

3. Nanoparticle-assisted RF-Induced Hyperthermia: *In vivo* studies

   Upon injection of PBS-suspended AuNPs and after the RF exposure treatment of ~2-3 weeks, posthumous analysis should reveal controlled tumor growth and/or a decrease in tumor size/mass (as shown in Figure 4). There may also be evidence of direct cellular thermal ablation. However, this may not be the case as simple citrate-capped AuNPs are far from being optimized and tend to aggregate within the tumor tissue. As can be seen in recent publications, AuNPs must be non-aggregated within intracellular organelles to enhance RF-induced cytotoxicity. Also, recent studies have shown that conjugation of chemotherapy drugs such as Gemcitabine to AuNPs optimizes the RF therapy. The investigator can still use these protocols however to directly compare the effectiveness of their own AuNP-complex in relation to our groups' previous work.
1. Assessing RF heating of NP colloids: AuNPs as an example.

Figure 1. Experimental overview. AuNP heating assessment: As-purchased AuNPs (1.a) are placed in a 50 kDa filter (1.b) and centrifuged down to separate the AuNPs from the filtrate (1.c). This allows for highly concentrated and purified AuNPs to be formed (1.d). The sample is then placed into the RF system using a Teflon sample holder mounted to an adjustable rotary stage (1.e). The AuNPs heating rates, as well as four other control areas, are recorded using an IR camera (1.f). In vitro protocols: Hep3B hepatic cancer cells are grown in the front 3-wells of several 12-well cell packs as shown in 2.a (the amount of cell-packs used depends on what the experimentalist wishes to investigate in terms of applied RF power, AuNP concentration, controls, etc.). Each 12-well plate is then subjected to the RF field (2.b). Although not necessary as the optimum RF exposure time has already been determined the media temperature can also be recorded using the IR camera (2.c). In vivo protocols: BALB-C mice bearing ectopic hepatic tumors (3.a) were subjected to intra-tumoral injections of AuNPs and exposed to the RF system (3.b) for several minutes. Copper tape was used to ground the mice in order to prevent skin burning. A quartz cuvette filled with AuNPs is also shown next to the mouse to validate RF exposure. The tumor area should have a temperature higher than the rest of the mouse and usually appears red in the IR picture (3.c).
Figure 2. Heating rates (°C/sec) of 5 nm and 10 nm diameter AuNPs solutions. As per protocol instructions, heating rates are determined for AuNPs with supernatant (AuNPs+SN), AuNPs filtered out so that only the supernatant is present (SN), and the difference in heating rates between these two (difference). Average heating rates are from three different experiments (A, B, and C).

Figure 3. Idealized Hyperthermia cytotoxicity viability (MTT assay). Shown are four cell experiments: control (no RF), AuNP only (no RF), RF only, and RF with addition of cellular internalized AuNPs (A, B, C, and D, respectively).
Figure 4. Posthumous analysis of ectopic mice tumors. The left-hand tumor is what would be expected from both control specimens i.e. no RF and no AuNP injection). The middle tumor shows a slight decrease in size when subjected to the RF field alone. However, the right-hand tumor shows that the RF+AuNP combined therapy can decrease/control the tumor growth even further.

Discussion

These protocols allow the experimentalist to fully analyze the extent to which nanomaterials (in this case AuNPs) can increase RF-induced hyperthermia for cancer treatment. The first protocol specifically deals with analyzing heat production from highly-concentrated and purified AuNP samples. Although other groups have reported heat production primarily from the buffers which the AuNPs are suspended in and not the AuNPs themselves, their RF systems used lower concentrations of AuNPs with diameters >10 nm, as well as lower RF operating powers with electric-field strengths <90 kV/m which are too low to see any noticeable RF heating effects from AuNPs. Only by following the protocols and parameters listed in this report can the experimentalist observe the nanoscale heat phenomenon.

The in vitro section allows development of cellular-RF-NP interfaces to be studied for optimized RF/NP-induced hyperthermia. Before addition of AuNPs and RF exposure, you should expect to have a viable 2D layer growth of the relevant cancer cell lines (in this case Hep3B). However, the correct RF exposure time for each cell line needs to be predetermined before these experiments by exposing cells to the RF field at different time points e.g. 2-8 min) and looking at their viability profile after 24 hr. The correct RF exposure time to use should be where the cells are ~80% viable. In the case of Hep3B cells this was found to be ~3.5 min.

The simplest assay of choice for viability is the standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, although another assay may be needed if it is anticipated that the NPs will interact with the assay reagents (as was the case with MTT assay reacting with CNTs). Other more advanced and detailed assays can be used to assess cell death mechanism such as FACS analysis with Annexin-V and propidium iodide (PI) staining. Future in vitro system developments within our group will look at placing the cells in a temperature-controlled RF-inert incubator to completely rule out any possible sources of hyperthermia due to bulk heating of the cell media. Also, the amount of AuNPs which need to be internalized within a cell for maximum cell death, as well as their stability within intracellular organelles, will be investigated in greater detail. This is in accordance with recent work which showed that AuNPs must be non-aggregated within lysosomes for enhanced RF-therapy.

Finally, in vivo protocols were described to allow for full bio-analysis of AuNPs in ectopic hepatic cancer mice models for their ability to control or decrease tumor growth and/or size in combination with RF therapy. An important point for discussion is the ability for the RF-field to induce skin burns on the mouse due to incorrect grounding procedures. The use of properly grounded and placed copper tape, as mentioned in the protocol section, is a requirement in order to stop these burns.

Future in vivo work in our lab will work on assessing the actual mechanism of tumor death/size control from RF-AuNP exposure. Although it is hypothesized that hyperthermia plays a critical role, this has to be validated though the use of such controls as direct insertion of optical-fiber thermal probes into the tumor and surrounding healthy cells to look at the RF-induced temperature response of such tissues. Also, the development of an intracellular fluorescent thermal dye whose emission wavelength is a direct function of temperature would be an excellent tool for this validation and could also be used for in vitro models.

Disclosures

We have nothing to disclose.
Acknowledgements

This work was funded by the NIH (U54CA143837), the NIH M.D. Anderson Cancer Center Support Grants (CA016672), the V Foundation (SAC), and an unrestricted research grant from the Kanzius Research Foundation (SAC, Erie, PA). We thank Kristine Ash from the Department of Surgical Oncology, M.D. Anderson Cancer Center, for administrative assistance.

References